CD Biosynsis offers comprehensive Sf9 Cells Genome Editing & Metabolic Engineering Solutions, utilizing a full suite of precision tools to modify the insect cell host for applications ranging from high-yield protein production to advanced vaccine development. Sf9 cells (derived from Spodoptera frugiperda) are the core host for the Baculovirus Expression Vector System (BEVS), highly valued for producing complex proteins, VLPs (Virus-Like Particles), and antigens that require correct folding and disulfide bond formation. Our solutions integrate advanced CRISPR-based technologies, including CRISPR-Cas9 for stable integration and multi-allelic deletion, Base Editing for single-nucleotide precision, and CRISPRi for tunable gene repression, with metabolic optimization. We specialize in providing highly efficient, stable, and verifiable modifications that accelerate the optimization of Sf9 cell lines for enhanced titer, improved product quality (e.g., humanized glycosylation), and robust bioprocessing performance.
Get a QuoteEffective strain engineering in Sf9 cells requires precise control over gene function—from permanent elimination (e.g., native proteases, non-human glycosylation enzymes) to subtle tuning (e.g., chaperone expression). Our integrated platform provides all necessary tools to achieve these goals, leveraging optimized delivery systems (RNP, Baculovirus) and specialized gRNAs tailored for the insect cell genome. This ensures accurate manipulation, including stable integration of humanized glycosylation pathways and precise control over host factors. This foundational capability is crucial for both optimizing commercial BEVS production and for creating superior VLP hosts.
Standard editing platform for targeted DNA double-strand breaks (DSBs), optimized for transient RNP delivery and utilizing NHEJ (for KO) and HDR (for KI) pathways in insect cells.
DSB-free system for highly efficient, clean single-nucleotide conversions (C>T or A>G), ideal for subtle tuning of promoters or enzyme activity to manage BEVS flux.
Tunable and reversible gene knockdown (repression) for safely optimizing the balance of host factors (e.g., chaperones) or metabolic enzymes without permanent lethality.
Permanent deletion or disruption of target genes (e.g., native proteases, glycosylation enzymes) via NHEJ to enhance product stability and humanize PTMs.
Accurate integration of expression cassettes (e.g., human glycosyltransferases) into the genome via HDR for stable, high-level expression and pathway assembly.
Simultaneous targeting of multiple genes or alleles using gRNA arrays to accelerate the construction of complex, optimized Sf9 strains.
Targeted engineering to reduce toxic byproducts, enhance energy supply, and manage chaperone expression for superior cell performance during high-titer production.
End-to-end service providing high-yield BEVS production and purification of complex proteins, VLPs, and antigens with guaranteed folding and PTMs.
Integrated HTS and editing to accelerate the creation of highly controlled, stable clones for maximizing product titer and quality in industrial scale-up.
A systematic process for rational design, precise editing, and stable clone isolation.
1. Rational Design & System Preparation
2. Transfection & Editing
3. Clone Isolation & Screening
4. Verification & Stable Cell Line Delivery
Identify all necessary genomic modifications (KO, KI, tuning). Design gRNAs for high on-target specificity.
Prepare the Cas9/BE/CRISPRi system (RNP/Plasmid) optimized for the insect host (Sf9/Hi5).
Design HDR repair templates (donor DNA) for Gene Knock-in of humanized pathways.
Deliver the editing components into the host cell line via optimized protocols (Electroporation or Transfection).
Culture cells to allow the repair mechanisms (NHEJ or HDR) to finalize the genomic edit.
Apply selection or FACS sorting to enrich for edited clones.
Genotype verification via junction PCR and sequencing of the edited locus to confirm clean edit.
Phenotypic validation of the final clone for stable expression and product functionality.
Delivery of the verified Master Cell Bank (MCB) or research cell line and comprehensive documentation.
Targeted BEVS Host Optimization
Expertise in engineering Sf9 and Hi5 cells, focusing on optimizing the BEVS chassis for high-titer production and robust protein folding.
Precision Glycoengineering
CRISPR-based editing (KO/KI) enables the elimination of immunogenic insect glycans and the insertion of human pathways for superior product quality.
Stable Genomic Integration
Preference for CRISPR/HDR-mediated knock-in guarantees consistent, high-level expression of heterologous pathways, avoiding transient expression variability.
Full CRISPR Toolset
Access to Cas9, Base Editing, and CRISPRi ensures the most appropriate tool is selected for any modification, from pathway disruption to chaperone tuning.
1. Which insect cell lines do you support for editing?
We support standard BEVS hosts including Sf9, Sf21, and High Five (Hi5) cells, optimizing protocols for each host's specific growth and transfection characteristics.
2. What is the role of Base Editing in Sf9 optimization?
Base Editing is used for subtle, DSB-free modifications, such as fine-tuning promoter strengths or optimizing codons in host factors (e.g., chaperones) to safely manage folding capacity without affecting the cell's basic survival.
3. How do you ensure the stability of the final engineered cell line?
Stability is ensured by using CRISPR/HDR to integrate the desired modifications (e.g., human glycosylation pathway genes) into verified genomic loci, making the trait permanent and stable over long passages.
4. Can you perform multiplex editing in Sf9 cells?
Yes. We use multiplex gRNA systems and RNP delivery to simultaneously target and disrupt or modify multiple genes (e.g., knocking out multiple native glycosylation enzymes) to accelerate complex chassis development.
5. Why is gene knockout common in Sf9 glycosylation engineering?
Sf9 cells naturally produce immunogenic glycans (e.g., alpha(1,3)-fucose). Gene knockout is essential for permanently eliminating the native insect enzymes responsible for these modifications before the human glycosylation pathway genes are inserted.
6. What delivery systems are used for the CRISPR components?
We use optimized systems: RNP (Ribonucleoprotein) for transient, high-efficiency edits; and plasmid for stable selection or integration into the BEVS system itself.
7. How is the final monoclonal cell line verified?
Verification includes single-cell cloning (FACS/limiting dilution), sequencing to confirm genotype (KI/KO), and phenotypic analysis (e.g., mass spectrometry for glycan profile, VLP assembly confirmation) to confirm the desired trait.
8. What is the primary role of CRISPRi in Sf9 bioproduction?
CRISPRi is used for tunable repression (knockdown) of genes, which is ideal for balancing metabolic flux or managing the expression of essential chaperones (folding capacity) without causing lethal permanent disruption.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.